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Summary
Background: In many parts of Asia, the inaccessibility and high cost of diagnostic tests
have hampered the study of community-acquired pneumonia (CAP) caused by atypical
respiratory pathogens.
Objective: This surveillance study examined the frequency of infection with Myco-
plasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila in
* Corresponding author. Tel.: +60 3 79502581; fax: +60 3 79584844.
E-mail address: ngeowyf@ummc.edu.my (Y.-F. Ngeow).
1201-9712/$30.00 # 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2004.06.006
Prevalence of atypical respiratory pathogens in community-acquired pneumonia 1451756 patients presenting with signs and symptoms of CAP at 12 medical centres in
Asia, using standardised laboratory techniques and interpretation criteria in all
participating centres.
Methods: Diagnosis of current infection was based on significant changes in antibody
titer or persisting high antibody titers, together with the presence of bacterial DNA in
respiratory secretions, in the case ofM. pneumoniae and C. pneumoniae infections, or
bacterial antigen in urine, in the case of L. pneumophila serogroup 1 infection.
Results: Using these criteria, results from 1374 patients with paired sera showed
that, overall, 23.5% of CAP cases were associated with infection with atypical
respiratory pathogens, with M. pneumoniae, C. pneumoniae, and L. pneumophila
being found in 12.2%, 4.7%, and 6.6% of cases, respectively. Persisting high antibody
titers indicative of past exposure to M. pneumoniae, C. pneumoniae, and L. pneu-
mophila were seen in 10.2%, 4.8%, and 18.9% of patients, respectively.
Conclusion: These data reflect the overall high prevalence of these atypical patho-
gens among Asian patients with CAP.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
The atypical respiratory bacteria Mycoplasma pneu-
moniae, Chlamydophila pneumoniae, and Legio-
nella spp. are increasingly recognised as common
and important pathogens in community-acquired
pneumonia (CAP).1 In a review, Vergis and Yu2 noted
that these atypical pathogens were responsible for
around 22% of CAP cases. Legionella spp. were
identified in 3—16% of patients, while M. pneumo-
niae and C. pneumoniae were found in 4—29% and
5—43% of patients with CAP, respectively.
Although studies to determine the prevalence of
these pathogens in various Asian countries have
been carried out and some of the data pub-
lished,3—9 there is still a paucity of good epidemio-
logical data on the frequency with which atypical
respiratory pathogens cause CAP in Asia. This has
been attributed to the relative inaccessibility and
high cost of laboratory diagnostic tests.
Because M. pneumoniae, C. pneumoniae, and
Legionella spp. are fastidious in their growth
requirements and their isolation is both time con-
suming and laborious, serology has traditionally
been used for diagnosis. However, the use of serol-
ogy is limited by the occurrence of cross-reactivity,
delayed or abated antibody response, and the
inability to differentiate present from past infec-
tions, especially when only a single serum sample is
available. Non-culture methods have been used to
demonstrate the presence of bacterial antigen or
nucleic acids in respiratory secretions as well as in
urine in the case of Legionnaires’ disease. However,
asymptomatic pharyngeal carriage has been
described for both Chlamydophila10 and Myco-
plasma,11 and thus detection of these organisms
in respiratory secretions contaminated by orophar-
yngeal flora may not always indicate current chla-mydial or mycoplasmal infection. A positive antigen
or DNA test corroborated by positive serology would
therefore provide stronger evidence of recent infec-
tion with these organisms.
This surveillance study was designed to deter-
mine the rates of infection by atypical respiratory
pathogens in patients with CAP in 12medical centers
in Asian countries, following the introduction of
standardised diagnostic tests for nucleic acid, anti-
gen and antibody detection of M. pneumoniae, C.
pneumoniae, and L. pneumophila.Patients and methods
Study design
This prospective study was conducted at 12 medical
centers (Beijing, Shanghai, Hong Kong, Seoul, Taipei,
Bangkok, Manila, Kuala Lumpur, Petaling Jaya,
Singapore, Jakarta, Surabaya) between October
2001 and December 2002, after prior approval was
received from the local Independent Review Board or
Ethics Review Committee in each country. Written,
informed consent was obtained from all patients, or
their legal representatives in the case of children,
before study enrolment. The study was carried out in
compliance with good clinical practice, including the
International Conference on Harmonization Guide-
lines and the Declaration of Helsinki.
Patients
Male and female subjects aged 2 years were eli-
gible for inclusion in the study provided that they
had a clinical and radiological diagnosis of CAP. This
required patients to have new infiltrates on chest X-
ray or consolidation that could not be attributed to
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the following signs and symptoms: cough; acute
changes in the quality of sputum; documented fever
or hypothermia within the preceding 24 hours; rales
or evidence of pulmonary consolidation; leukocyto-
sis or malaise; and myalgia or gastrointestinal symp-
toms. Both outpatients and hospitalised patients
with CAP were included in the study. All eligible
patients were required to undergo serologic tests on
paired acute- and convalescent-phase sera, as well
as tests for bacterial antigen in urine and polymer-
ase chain reaction (PCR) on respiratory samples
collected at baseline.
Patients with evidence or history of tuberculosis,
nosocomial pneumonia, lung cancer, aspiration
pneumonia, or bronchiectasis were excluded from
the study. Those who were HIV positive or who had
been hospitalised within two weeks prior to con-
sultation were also excluded.
Laboratory tests
A training workshop was held prior to the start of the
study to ensure that all centers performing labora-
tory analyses used standardised laboratory techni-
ques and interpretation criteria. An External Quality
Assurance Systemprogramwas also carried out twice
during the study to assess the competency of parti-
cipating laboratories in Chlamydophila microimmu-
nofluorescence (MIF) serology and PCR assays.
For the purpose of serologic testing, blood sam-
ples (5—8 mL) were collected aseptically from
patients. Acute sera were stored at 20 8C until
convalescent sera, obtained 2—8 weeks after the
acute specimen, were available to be tested simul-
taneously. Sputum (or throat swabs when sputum
could not be collected), nasopharyngeal aspirates,
bronchoalveolar lavage, and samples of pleural fluid
suitable for PCR analysis were stored in PCR buffer in
2 mL vials at 20 8C before testing. Urine samples
were collected in sterile containers and either pro-
cessed within 24 hours of collection or stored at 4 8C
for up to 14 days or 20 8C for longer periods.
Specific antibodies (IgG and IgM) to M. pneumo-
niae were measured using a particle agglutination
test (Serodia Myco II, Fujirebio, Japan). A modified
MIF test (Focus Technologies, USA) using purified
elementary bodies diluted in egg yolk sac was used
to measure specific IgG antibodies to C. pneumo-
niae, C. psittaci, and C. trachomatis. Legionella
antibodies were detected by an indirect immuno-
fluorescence antibody test (MarDx Diagnostics Inc.,
USA) for IgG antibodies to L. pneumophila ser-
ogroups 1—7. For the qualitative detection of L.
pneumophila serogroup 1 soluble antigen in urine,
specimens were tested by a microtiter enzyme-linked immunosorbent assay (Biotest Legionella
Urine Antigen EIA, Biotest AG, Dreieich, Germany).
Samples with optical density (OD) values above the
cutoff value (mean OD of the negative control +.20)
were considered presumptive evidence of current or
past infection. Tests for Legionella infection were
only carried out on adult patients.
PCR assays for the detection of M. pneumoniae
and C. pneumoniae nucleic acids were performed as
previously described with primers targeting the p1
adhesin gene of M. pneumoniae12 and the 16S rRNA
gene of C. pneumoniae.13 The presence of a PCR
product of 463 bp size or 209 bp size on gel electro-
phoresis was considered indicative of infection with
C. pneumoniae or M. pneumoniae, respectively.
Criteria for an etiological diagnosis
Current infection with M. pneumoniae, C. pneumo-
niae, or L. pneumophila was based on a four-fold or
greater rise in antibody titer between paired acute-
and convalescent-phase sera. Results of single
serum samples were excluded from the analysis.
In cases where both serum samples showed high
antibody titers (1:160 for M. pneumoniae,
1:512 for C. pneumoniae IgG, and 1:256 for L.
pneumophila IgG), the presence of mycoplasmal or
chlamydial DNA in respiratory secretions or legio-
nella antigen in urine was also considered indicative
of a current infection. The presence of a positive
PCR for M. pneumoniae or C. pneumoniae in the
absence of a positive serologic response was inter-
preted as possible carriage.Results
Patient characteristics
Of a planned total of 1800 patients (a maximum of
200 patients from each of nine countries), 1756
patients with a diagnosis of CAP were enrolled in
this study, comprising 1263 adults and 493 children.
Paired sera were obtained from 1374 patients (926
(73.3%) adults and 448 (90.9%) children), and pro-
vided the basis for estimating the rates of infection
caused by the three atypical respiratory pathogens.
Table 1 summarises the demographic data and
clinical status at baseline of the 1374 adult and child
patients included in the epidemiological analyses.
Failure to obtain paired serum samples on 337 adults
and 45 children enrolled in the study was mainly due
to loss to follow-up (230 adults; 27 children). Other
reasons were suspected nosocomial pneumonia/
lung cancer/aspiration pneumonia/bronchiectasis
at screening (22 adults; 16 children), suspected
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Table 1 Patient demographic data and clinical status at baseline of patients with an etiologic diagnosis of
community-acquired pneumonia.
Variable Paediatric patients (n = 448) Adult patients (n = 926)
Male/female 245/203 537/389
Age 327 (2—5 years) 56 (16—20 years)
121 (6—15 years) 330 (21—50 years)
540 (51 years)
Outpatient (%) 58 (12.9) 105 (11.3)
Inpatient open ward (%) 384 (85.7) 765 (82.6)
Inpatient ICUa (%) 6 (1.3) 56 (6.0)
Signs and symptoms (%)
Cough 448 (100) 897 (96.9)
Fever 434 (96.9) 787 (85.0)
Chills or rigors 85 (19.0) 398 (43.0)
Pleuritic chest pain 38 (8.5) 320 (34.6)
Dyspnea 247 (55.1) 462 (49.9)
Malaise 267 (59.6) 506 (54.6)
Myalgia 44 (9.8) 306 (33.0)
Diarrhea 65 (14.5) 50 (5.4)
Wheezing 107 (23.9) 126 (13.6)
Rales/crepitations 376 (83.9) 646 (69.8)
Rhonchi 195 (43.5) 239 (25.8)
Bronchial breath sounds 33 (7.4) 171 (18.5)
Co-morbidity (%)
Asthma 70 (15.6) 67 (7.2)
Congestive heart failure 7 (1.6) 72 (7.8)
COPDb 2 (0.4) 126 (13.6)
Diabetes mellitus 0 (0) 133 (14.4)
Hepatic disease 2 (0.4) 27 (2.9)
Impaired renal function 1 (0.2) 45 (4.9)
Other 48 (10.7) 203 (21.9%)
a ICU, intensive care unit.
b Chronic obstructive pulmonary disease.tuberculosis at screening (12 adults; one child), and
death (73 adults; one child). The average time
between acute and convalescent sera being taken
was 24 days for adults and 21 days for children.
Most patients who enrolled in this study were
admitted to hospital for treatment of CAP. Among
the 821 (88.7%) adult inpatients, 56 (6%) required
treatment in the intensive care unit (ICU), while
only six (1.3%) of the 390 (87.1%) children admitted
to hospital required ICU treatment.
Occurrence of CAP
Across the 12 centres surveyed, cases of CAP
occurred throughout the study period, suggesting
that these infections are endemic in the region.
Infections due to atypical pathogens
On the basis of a four-fold or greater increase in
antibody titer between acute- and convalescent-
phase sera, 19.9% of the study population hadCAP associated with atypical pathogens (Table 2).
Rates of current infection with M. pneumoniae, C.
pneumoniae, and L. pneumophila were 9.4%, 4.3%,
and 6.2%, respectively. The figures for infection with
L. pneumophila were derived from adult patients
only, since children with CAP were not screened for
legionellosis. When the serology results were com-
bined with those from the antigen detection tests,
or PCR, the overall current infection rate due to
atypical pathogens increased to 23.5%. Based on
these criteria, rates of current infection with M.
pneumoniae, C. pneumoniae, and L. pneumophila
were 12.2%, 4.7%, and 6.6%, respectively (Table 2).
However, using PCR and urine antigen test results
alone, overall infection rates decreased for all
atypical pathogens to 8.7% for M. pneumoniae,
2.5% for C. pneumoniae, and 2.5% for L. pneumo-
phila (Table 3).
Among adult patients, the highest overall infec-
tion rates were seen in Manila (43.4%), Beijing
(35.0%), and Bangkok (29.8%) (Table 4). Among
paediatric patients, overall infection rates ranged
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Table 2 Rates of current infection with Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella
pneumophila in the adult and paediatric populations with acute and convalescent sera.
Etiology Paediatric patients
(n = 448)
Adult patients (n = 926) Total (n = 1374)
Serology Serology
plus PCRa or
EIAb positive
Serology Serology
plus PCRa
or EIAb positive
Serology Serology
plus PCRa or
EIAb positive
M. pneumoniae (%) 41 (9.2) 61 (13.6) 88 (9.5) 106 (11.4) 129 (9.4) 167 (12.2)
C. pneumoniae (%) 8 (1.8) 11 (2.5) 51 (5.5) 54 (5.8) 59 (4.3) 65 (4.7)
L. pneumophila (%) NDc NDc 57 (6.2) 61 (6.6) 57 (6.2) 61 (6.6)
Total (%) 49 (11.0) 72 (16.1) 196 (21.2) 221 (23.8) 245 (19.9) 293 (23.5)
a Polymerase chain reaction.
b Enzyme-linked immunosorbent assay.
c Not done.
Table 3 Rates of current infection with Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella
pneumophila in the adult and paediatric populations based on PCRa and urine antigen results.
Paediatric patients (n = 482) Adult patientsc Total
Mycoplasma PCRa positive (%) 59 (12.2) 86 (7.3) 145 (8.7)
Chlamydophila PCRa positive (%) 9 (1.9) 33 (2.8) 42 (2.5)
Legionella urine Ag positive (%) NDb 25 (2.5) 25 (2.5)
a Polymerase chain reaction.
b Not done.
c N = 1177 for Mycoplasma and Chlamydia. N = 1011 for Legionella.from 3.9% (Kuala Lumpur/Petaling Jaya) to 18%
(Bangkok). Mycoplasma pneumoniae infected more
children (13.6%) than adults (11.4%), while the
reverse was true of C. pneumoniae (2.5% vs. 5.8%)
(Table 2).
Persisting high antibody titers (1:160 for M.
pneumoniae, 1:512 for C. pneumoniae IgG, and
1:256 for L. pneumophila IgG) were seen in 10.2%
(M. pneumoniae), 4.8% (C. pneumoniae), and 18.9%
(L. pneumophila) of patients. These titers have
been considered as diagnostic cutoff titers by
others, but have not been included in the definitionTable 4 Number of CAPa cases with paired sera and
percent infection by Mycoplasma pneumoniae, Chla-
mydophila pneumoniae, and Legionella pneumophila
in children and adults in the centres surveyed.
Centre Children (%) Adults (%)
Beijing NDb 103 (35.0)
Shanghai 69 (17.4) 140 (18.6)
Hong Kong NDb 62 (6.5)
Seoul NDb 131 (6.1)
Taipei 108 (13.9) 85 (18.8)
Bangkok 245 (18.0) 47 (29.8)
Manila NDb 136 (43.4)
Kuala Lumpur, Petaling Jaya 26 (3.9) 112 (26.8)
Jakarta, Surabaya NDb 37 (5.4)
Singapore NDb 73 (12.3)
a Community-acquired pneumonia.
b Not done.of current infection in this study as there is little
information on the population background antibody
levels in the countries surveyed. When these results
are included in the analysis, the overall presence of
the three atypical respiratory pathogens is 57.4%.
Notably more children than adults had persisting
high titers for M. pneumoniae (19.4% vs. 5.7%),
while similar titers for C. pneumoniae were more
frequently seen in adults (3.1% vs. 5.6%).
Mixed infections occurred in 18 patients. Nine
had concurrent infections with M. pneumoniae and
C. pneumoniae, five with C. pneumoniae and L.
pneumophila, and four with M. pneumoniae and
L. pneumophila. No attempt was made to analyse
the concurrent infection with other microbial
pathogens such as Streptococcus pneumoniae and
respiratory viruses, as the diagnostic tests for these
pathogens were not standardised.
Co-morbidity was much more common among
adult CAP patients than children, with diabetes
and chronic obstructive pulmonary disease (COPD)
being the most common underlying diseases. Apart
from asthma, which affected 70 (15.6%) children
with CAP, other serious underlying diseases were
rare in children. In adults, especially elderly
patients, infection with C. pneumoniae was asso-
ciated with the highest rate of ICU admission, occur-
ring in 16.1% of all adult CAP admissions to ICU
compared with 7.1% for L. pneumophila and 3.6%
for M. pneumoniae. Expressed as a percentage of
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Figure 1 Distribution of adult and paediatric patients with infections due to atypical pathogens in outpatient and
inpatient settings. ICU, intensive care unit.infections identified, 16.7% of all C. pneumoniae
infections enrolled into the study occurred in
patients requiring ICU admission while the same
was true for 6.6% of L. pneumophila and 1.9% of
M. pneumoniae infections. Figure 1 summarises the
distribution of outpatients and inpatients (open
ward and ICU) for both adults and children with
the three infections in this study.
About half of the patient population had received
antibiotic therapy prior to screening; 50.4% of those
infected with M. pneumoniae, 49.1% with L. pneu-
mophila, and 28.8% with C. pneumoniae.Discussion
Establishing an etiologic diagnosis of CAP has always
proved difficult, with the causative organisms often
isolated in as few as 30—50% of cases, especially
where infection is due to atypical respiratory patho-
gens.1,14,15 In the present Asian surveillance study to
determine the infection rates of atypical pathogens
in adults and paediatric patients with CAP, directantigen and DNA tests were combined with the
results of serologic tests on paired sera, the use
of which has been shown to increase diagnostic
yield.16 Importantly, all of the participating labora-
tories in the different countries used the same
standardised diagnostic procedures and interpreta-
tion criteria. A quality assurance program was also
instituted to ensure consistency between partici-
pating laboratories, enabling results to be inter-
preted with confidence. The collection of paired
sera from 73% of adults and 90% of children, com-
pared with much lower return rates of 31—44% in
other studies,8,17 helped increase the reliability of
the data analysed.
A major limitation in this study is the lack of
sputum cultures for other known pathogens of CAP
to help determine the clinical significance of the
three atypical bacteria studied. On the other hand,
these atypical bacterial infections were diagnosed
by the presence of a significant immune response.
Hence, although immune response does not indicate
the site of infection, a causative role for the atypical
pathogens in the lower respiratory tract cannot be
150 Y.-F. Ngeow et al.ruled out. Both C. pneumoniae and M. pneumoniae
are known to have a toxic effect on ciliated epithe-
lium.18,19 They could be the sole causative agents or
initiators of infection, priming the airways for co-
infection with other typical and atypical respiratory
pathogens. It is often difficult to know which patho-
gen in a mixed infection is the more important cause
of disease. Even if the atypical bacterial infections
had occurred in the presence of other causes of CAP,
they should be regarded as potential contributors to
diseases that require treatment with specific anti-
biotics.
Atypical pneumonia by itself could be associated
with serious illness, especially in elderly patients
with underlying disease. Such cases often necessi-
tate treatment in the ICU. Severe CAP due to infec-
tion with C. pneumoniae has been described
previously.20—23 In this study, it was the atypical
pathogen most frequently associated with ICU
admissions. This is contrary to the belief that Legio-
nella pneumonia is associated with more morbidity
than the other two atypical bacteria, and despite
the fact that more (55.7%) L. pneumophila infec-
tions in this study occurred in patients over 51 years
of age compared to C. pneumoniae infections
(41.5%). Nevertheless, all except one of the cases
with chlamydial infection admitted to ICU were over
50 years of age and 66% had diabetes mellitus and/or
chronic renal, cardiac or respiratory disease. How-
ever, it is again not known if the chlamydial infec-
tion was the main cause of ICU admission.
Despite limitations, the results of this surveil-
lance study carried out in 12 Asian medical centers
illustrate the importance of atypical respiratory
pathogens in the etiology of CAP. Collectively, M.
pneumoniae, C. pneumoniae, and L. pneumophila
were found to be associated with at least 20—24% of
acute cases of CAP among patients living in major
cities and attending tertiary medical centers in
mainland China, Taiwan, Hong Kong, Korea, Thai-
land, Malaysia, Singapore, Philippines, and Indone-
sia. Notwithstanding differences between studies in
the choice of diagnostic method for identifying
atypical pathogens, these findings are broadly con-
sistent with data from other Asian surveillance stu-
dies (Table 5). Wattanathum et al.6 found that
atypical pathogens were responsible for a high pro-
portion of adult cases of CAP in both hospitalised and
outpatients in Thailand; 36.7% of outpatients were
infected with C. pneumoniae and 29.6% with M.
pneumoniae, while the corresponding rates in inpa-
tients were 16.3% and 6.8% respectively. Similarly, a
study in Korea identified C. pneumoniae as the
leading cause of adult atypical pneumonia
(12.3%), followed by M. pneumoniae (8.6%).8 As in
Thailand and South Korea, chlamydial infectionswere more often identified than mycoplasmal infec-
tions in Hong Kong5 but in previous studies from
Malaysia, Taiwan and Singapore, the reverse
appears to be true. In the present study of mostly
inpatients, M. pneumoniae was found to be the
major atypical bacterial pathogen in both adult
and paediatric patients in all participating centres,
except Hong Kong, where chlamydial pneumonia
(3.2%) was diagnosed twice as frequently as myco-
plasmal pneumonia (1.6%). Elsewhere, adult M.
pneumoniae infection rates ranged from 2.7% (Indo-
nesia) to 28.2% (Beijing) while the corresponding
rates for C. pneumoniae were from 0% (Singapore,
Indonesia) to 10.6% (Bangkok) and 10.7% (Malaysia).
Among paediatric patients, 3.8% (Malaysia) to 15.9%
(Shanghai) of CAP cases were associated with M.
pneumoniae while C. pneumoniae was found in only
0% (Malaysia) to 3.3% (Bangkok) of cases. The pre-
dominance ofM. pneumoniae infections among chil-
dren and young adults with CAP is in accordance with
other published studies from the region.20,24—26
In Asian communities, the frequency of CAP due
to L. pneumophila appears to be relatively low,
possibly because of difficulties associated with the
diagnosis of this pathogen.9 In their survey, Lee et
al. did not find any L. pneumophila infections among
81 Korean patients consecutively diagnosed with
CAP over a 12-month period.8 However, using diag-
nostic methods similar to those employed in the
present study, Wattanathum et al.6 identified L.
pneumophila as the cause of acute CAP in 8.2% of
outpatients and 5.4% of hospitalised patients in
Thailand— frequencies similar to the overall current
infection rate in adult patients described here.
Inter-country differences are expected as Asia is
a vast continent with a diversity of climates, geo-
graphies and human activities. In this study there
was a marked difference between the current infec-
tion rate for Manila (25.0%) and those of other
countries (range 0—5.3%; mean 3.5%). Although
32.4% of the legionella infections in Manila occurred
in the month of January 2002, there were still one to
four cases per month over most of the study period.
Hence, even when the possible outbreak in the
month of January 2002 was excluded, the occur-
rence of L. pneumophila infections in Manila (16.9%
of CAP cases) was still very much higher than that in
other study centers. Further studies have been
planned to investigate this unusually high infection
rate in Manila.
Parallel to the difference in infection rates, the
occurrence of persisting high antibody titers also
ranged from 2.4% in Taipei and 4.3% in Shanghai,
where the current infection rates were low, to 44.1%
in Manila and 55.3% in Bangkok. Although some of
these background antibody titers could be the result
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Table 5 Prevalence of atypical pathogens in CAPa patients in Asia.
Country/study population Diagnostic method Percent due to
C. pneumoniae
Percent due to
M. pneumoniae
Percent due to
Legionella spp.
Reference (s)
Thailand/499 patients Complement fixation 12.0 3
Thailand/426
patients aged 13—21 years
Complement fixation 24.4 4
Hong Kong/90 patients 5.6 3.3 5
Thailand/245 adult patients Culture/serology/urine
antigen tests
16.3 inpatients;
36.7 outpatients
6.8 inpatients;
29.6 outpatients
5.4% inpatients;
8.2% outpatients
6
Thailand/80 adult patients EIAb serology 26.2 7
Korea/81 adult patients Particle agglutination test/EIAb/IFAc 12.3 8.6 No cases detected 8
Malaysia/170 paediatric patients Particle agglutination test 23.5 20
Malaysiad Particle agglutination test/IFA/IFA 10.0—15.0 21.3 of 1735 patients;
35 in 6—20 age group
16.2
Korea/588 inpatients 5.0 4.0 2.0 e
Taiwan/pediatric patients 10.0—15.0 35.0—40.0 0.0—5.0 f
Singapore Particle agglutination test/CFT/IFA 0.3 of 333 patient
samples
12.1 of 3413 patient
samples
1.2/100,000 population g
a Community-acquired pneumonia.
b Enzyme-linked immunosorbent assay.
c Indirect fluorescent antibody.
d Yun-Fong Ngeow, University Malaya (unpublished).
e Seung-Chul Park, Korea University (unpublished).
f Ping-Ing Lee, National Taiwan University Hospital (personal communication).
g Mavis Yeo, Singapore General Hospital (personal communication).
152 Y.-F. Ngeow et al.of cross-reactivity with other bacteria like Helico-
bacter pylori,27 they could still be evidence of pre-
vious exposure to L. pneumophila, which suggests
that this organism should not be overlooked as a
potential cause of CAP in Asia.
In conclusion, this Asian surveillance study has
shown that M. pneumoniae, C. pneumoniae, and L.
pneumophila are frequently associated with CAP
among people living in the major urban areas of
east and south-east Asia. Given the relatively small
size of the study population and the recruitment
bias possibly introduced by the need to obtain
informed consent and paired sera, the results of
this survey cannot be extrapolated to the entire
Asian population. Nonetheless, they suggest an
important role for atypical respiratory pathogens
in the etiology of CAP in Asian patients and that the
prevalence of these infections is similar to that
observed inmany western countries.6,9 Recent Asian
guidelines support the empirical use of antibiotics
for the treatment of CAP due to atypical patho-
gens,28,29 although local epidemiologic data on pre-
valent pathogens should still be considered.Acknowledgements
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